SATELLOS Expands Leadership Team with New CFO Appointment | September 5, 2023 |
SATELLOS Announces Appointment of Chief Medical Officer | June 7, 2023 |
SATELLOS Announces Grant of Stock Options | June 1, 2023 |
SATELLOS Announces Development Candidate | January 3, 2023 |
SATELLOS Announces Q3 2022 Financial Results and Operational Highlights | November 23, 2022 |
SATELLOS Announces OTCQB Listing in the United States | October 6, 2022 |
SATELLOS Announces Closing of Offering of Units | September 13, 2022 |
SATELLOS Announces Pricing of Proposed Offering of Units | August 31, 2022 |
SATELLOS Reports Q2 2022 Financials and Operating Results | August 29, 2022 |
SATELLOS Announces Proposed Offering of Units | July 11, 2022 |
SATELLOS to present at Bio International Convention 2022 | June 14, 2022 |
SATELLOS to Present at the LD Micro Invitational | June 1, 2022 |
SATELLOS to Participate at BIO CEO & Investor Conference 2022 | February 10, 2022 |
Shareholder Letter from CEO | January 24, 2022 |
SATELLOS to participate at BIOTECH SHOWCASE™ Virtual 2022 | January 10, 2022 |
SATELLOS Announces New Board Appointments | December 6, 2021 |
SATELLOS Announces Evidence for Regeneration in Severe Model of Duchenne | September 13, 2021 |
SATELLOS Announces Partnership with Jesse’s Journey | August 25, 2021 |
SATELLOS and iCo Announce Completion of Reverse Takeover | August 13, 2021 |
iCo Therapeutics Inc. Announces Warrant Exercises | March 11, 2021 |
iCo Therapeutics Inc. Proposes to Re-Price Warrants | January 11, 2021 |
iCo Therapeutics Announces Third Quarter 2020 Financial Results | November 24, 2020 |
iCo Therapeutics Announces Option Grants | October 26, 2020 |